Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, Johansson KA, Ekberg L, Morhed E, Paludan M, Wittgren L, Blomgren H, Lewensohn R. Baumann P, et al. Among authors: paludan m. Acta Oncol. 2006;45(7):787-95. doi: 10.1080/02841860600904862. Acta Oncol. 2006. PMID: 16982541
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.
Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JS, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Baumann P, et al. Among authors: paludan m. Radiother Oncol. 2008 Sep;88(3):359-67. doi: 10.1016/j.radonc.2008.07.019. Epub 2008 Sep 1. Radiother Oncol. 2008. PMID: 18768228 Clinical Trial.
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Baumann P, et al. Among authors: paludan m. J Clin Oncol. 2009 Jul 10;27(20):3290-6. doi: 10.1200/JCO.2008.21.5681. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414667 Clinical Trial.
Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component.
Fokdal L, Tanderup K, Hokland SB, Røhl L, Pedersen EM, Nielsen SK, Paludan M, Lindegaard JC. Fokdal L, et al. Among authors: paludan m. Radiother Oncol. 2013 Apr;107(1):63-8. doi: 10.1016/j.radonc.2013.01.010. Epub 2013 Feb 26. Radiother Oncol. 2013. PMID: 23452917
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J. Ruhlmann CH, et al. Among authors: paludan m. Lancet Oncol. 2016 Apr;17(4):509-518. doi: 10.1016/S1470-2045(15)00615-4. Epub 2016 Mar 4. Lancet Oncol. 2016. PMID: 26952945 Clinical Trial.
12 results